EOADYUVANTE PHASE 2 STUDY USING GEMCITABIN ASSOCIATED WITH DOXORRUBICINE FOR THE TREATMENT OF BREAST CANCER CLINICAL STAGE III-B

Not Applicable

• Conditions: -C50 Malignant neoplasm of breast; Malignant neoplasm of breast; C50

• Registration Number: PER-003-00
• Lead Sponsor: ELI LILLY INTERAMERICA INC.,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2000-01-21
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

NA

Exclusion Criteria

NA

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br>Outcome name:NA<br>Measure:NA<br>Timepoints:NA<br>

Secondary Outcome Measures

Name	Time	Method
<br>Outcome name:NA<br>Measure:NA<br>Timepoints:NA<br>